Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Keep fighting the good fight to make it a more just world!
Not sure if intentional, but I liked the "doggone" simile to my screen name (though it is actually an homage to Zen master Dogen and rotation & move of the "u" in my name Doug)j.
After watching The Trial of the Chicago 7 movie Friday night, one moment stuck in my mind is just after former US AG Ramsey Clark's shocking testimony was denied it's hearing by the jury and he whispered to the defense attorney "Start working on the appeal."
I see parallels (albeit flipped political party affiliations) here in a judge either so biased or unethical to be able to see and rule in favor of the truth.
Amarin is reading this investors hub message board. Following this recent post, they have removed the link to out of date "Downloads" section of website from the bottom of their investors page!
THANK YOU AMARIN for paying attention to investor concerns!
No, it is out of date...if you click "last" it takes you to 2008-2011 posts. You can also filter by year at top and confirm nothing added to this website section since April 2019. It seems to be a useless section of website they can eliminate... the FAQ and Press Release sections are kept up to date fine. It's access by scrolling to bottom of investors page and clicking "DOWNLOADS" link in center.
As you acknowledge it's been posted elsewhere (just noting I found another link, not sure it's the same source), just adding your question is a very good one:
Your link isn't pulling up any article for me, but this link with similar title points to March 16 Financial Express story by Jefferies ... same article perhaps? Article is recommending Dr. Reddy's Labs as Buy, but looks more bullish for AMRN.
Pharma Customer Engagement Europe tomorrow (500 attendees)
I recall this was already posted, but Amarin's newly named CEO/President KM is speaking here in just over 6 hours (10 am Central European Time = 6 am Eastern Daylight Time). Anyone going or have access?
Also the very first item on agenda of Day 1 (good visibility for Amarin):
I think AMRN is right to continue to play their cards showing intent to GIA, with the hiring this new CEO with the best experience to succeed at GIA in EU. They need time for share price to recover higher to get a higher BO price to maximize shareholder value. I have confidence that they are laser focused on maximizing shareholder value, and intend to hold my shares regardless of near term market gyrations.
Looking recently to learn more about the BOD, I found this bio of Amarin's chairman of the board, Lars Ekman, very interesting... in his main position for Sofinnova Investments, the goal is clearly nurturing and launching successful drug companies until they "graduate." I have no doubt he's working to move Amarin from the list of "Active Companies" to the list of "Alumni Companies" on his bio page. His last "graduate", Spark Therapeutics, a gene therapy company, was sold to Roche for $4.8B in 2019.
Spark's chart (symbol ONCE) looked similar to AMRN... GIA until it's not, dropping from peak of $92.39 on July 1, 2018 to $34.70 on Dec. 24, 2018, clawing it's way back to $51.56 on Feb. 22, 2019, popping the next trading day to $113.48 on Feb. 25, 2019 on the day the acquisition agreement at $114.50/share was announced here.
Respectful yet strong reply. Thank you again, from a relative newcomer on iHub but longtime AMRN shareholder since just before Reduce-it spike but considerably in the hole nonetheless, for your tireless efforts to restore lost value to so many suffering investors who believe in the science, potential and validity of the patent protection for icosapent ethyl. May Judge Du be open to seeing the truth and correcting the error.
Thank you, Hikma attorney, for this link to remind us why we are disgruntled. The primary dictionary definition of "disgruntled" shows that it is not primarily a negative, pejorative term:
The secondary definition is sometimes co-opted to reflect poorly on those disgruntled, but the primary one invites one to ask "why" are they displeased and discontented. Thank you for providing the link to remind us of Judge Du's inappropriately describing the unique, patented chemical molecule contained in Vascepa as "Fish Oil," revealing either a predisposed bias or lack of understanding of the science.
Those of us who carefully did our due diligence understanding the science behind Vascepa (now approved and protected for 10+ years for distribution in Europe) have very good reason to be quite a bit displeased and discontented that the incorrect court case ruling just over a year ago caused many of us to lose thousands of dollars which we want rightfully restored to us. We now see the truth clearly, due to the hard work of other investors, that this patent decision was based on error and possibly fraud. Who is now pointing in the other direction and saying "look over there" and why?
I was not part of the crowdfunding, but have learned a great deal from reading the intelligent, well-reasoned, sound arguments in the Rule 60 filing, not to mention those in the Supreme Court writ of certiorari amicus briefs. As a careful, Ph.D. educated engineer, I take offense at your characterization of those who are working hard to reveal and promote what is really the truth in this unfortunate saga. Marjac is one of the most articulate, level-headed, intelligent and trustworthy individuals of those I've read. You sir, Hikma attorney, are not.
Approach Judge Du with respect, be well prepared, and know she highly values integrity and reputation. Also, being new to patent law, she may be open to correcting the error highlighted in the Rule 60 filing. Fingers crossed.